PPD, Inc. (PPD) – Press Releases
-
Saama Appoints Scott Rogers as Company’s Chief Financial Officer
-
Thermo Fisher Scientific Completes Acquisition of PPD, Inc.
-
PPD Named to ‘Best Workplaces in Greater China’ for Second Consecutive Year
-
PPD Named ‘Best Vaccine CRO of the Year’ in Asia-Pacific
-
PPD Wins Multiple Awards at Clinical Researcher of the Year Competition
-
PPD Reports Third Quarter and Year-To-Date 2021 Results
-
Medable Secures $304 Million in Funding at $2.1 Billion Valuation; New Round Co-Led by Blackstone Growth, GSR Ventures and Tiger Global
-
PPD Named Clinical Research Company of the Year for Second Consecutive Year
-
PPD Announces Third Quarter 2021 Earnings Conference Call
-
Society for Clinical Research Sites Names PPD Winner of Prestigious Eagle Award
-
Aethlon Medical Announces Contracting with PPD to Advance Hemopurifier Clinical Programs
-
PPD Earns Gold Award for Excellence in Employee Learning and Development
-
PPD Receives Award Recognizing Employee Talent Development
-
PPD Reports Second Quarter and Year-To-Date 2021 Results
-
PPD Recognized as a Best Place to Work in Asia
-
PPD Announces Second Quarter 2021 Earnings Conference Call
-
PPD Named ‘Most Innovative CRO’ by Triangle Business Journal
-
PPD Opens Multipurpose Clinical Research Laboratory in Suzhou, China
-
CRO Leadership Awards Recognize PPD for Excellence for 10th Consecutive Year
-
SHAREHOLDER ALERT: WeissLaw LLP Reminds VER, CBAN, WRI, and PPD Shareholders About Its Ongoing Investigations
-
PPD Named “Best CRO” at Vaccine Industry Excellence Awards
-
PPD to Expand GMP Lab in Ireland to Enhance Biopharmaceutical Testing Capabilities
-
PPD Reports First Quarter 2021 Results
-
PPD and Science 37® Strengthen Collaboration to Advance Decentralized Clinical Trials and Accelerate Development
-
PPD ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of PPD and Encourages Investors to Contact the Firm
-
Medable Secures Another $78 Million Funding to Fuel Digital Innovation for Patient-Centered Drug Development
-
Thermo Fisher Scientific to Acquire PPD, Inc., a Leading Clinical Research Organization
-
AzurRx BioPharma Engages PPD to Manage Clinical Trial for Niclosamide as Treatment for Grade 1 Immune Checkpoint Inhibitor-Associated Colitis
-
PPD Announces First Quarter 2021 Earnings Conference Call
-
AzurRx BioPharma Initiates Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections
-
PPD and Clinical Ink Collaborate on Innovative Process for Lupus Assessment and Near Real-Time Access to Endpoint Data
-
PPD Named a Leader in Digital Clinical Trial Solutions by ISG
-
PPD Lights Up Headquarters Downtown for 2021 Rare Disease Day
-
PPD to Present at Barclays Global Healthcare Conference
-
PPD Reports Fourth Quarter and Full Year 2020 Results
-
PPD Awarded US Army Study to Help Develop Post-Traumatic Stress Disorder Drugs
-
PPD Honored for Employee Development Programs that Deliver Results for Customers
-
AzurRx BioPharma Engages PPD to Manage Clinical Trial for Niclosamide as Treatment for COVID-19 Gastrointestinal Infections
-
PPD Announces Fourth Quarter and Full-Year 2020 Earnings Conference Call
-
PPD to Present at the 39th Annual J.P. Morgan Healthcare Conference
-
Moderna Announces FDA Authorization of Moderna COVID-19 Vaccine in U.S.
-
PPD Recognized as a Best Place to Work in Greater China
-
Moderna Announces Primary Efficacy Analysis in Phase 3 COVE Study for Its COVID-19 Vaccine Candidate and Filing Today with U.S. FDA for Emergency Use Authorization
-
Medable Secures $91 Million Funding to Accelerate Industry Shift to Digital and Decentralized Clinical Trials
-
Moderna Announces Supply Agreement with United Kingdom Government to Supply mRNA Vaccine Against COVID-19 (mRNA-1273) if Approved for Use
-
Moderna’s COVID-19 Vaccine Candidate Meets its Primary Efficacy Endpoint in the First Interim Analysis of the Phase 3 COVE Study
-
PPD Named Clinical Research Company of the Year
-
PPD Reports Third Quarter and Year to Date 2020 Results
-
Accelerated Enrollment Solutions Wins SCRS Site Tank Award
-
Moderna Completes Enrollment of Phase 3 COVE Study of mRNA Vaccine Against COVID-19 (mRNA-1273)
Back to PPD Stock Lookup